All In Biotech

Drug Trial Radar · NCT03781167

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

244

Actual

Start

Apr 29, 2019

Primary completion

Aug 17, 2022

Study completion Aug 17, 2022

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess the safety and tolerability of ABBV-951 (Foslevodopa/Foscarbidopa) in participants with Parkinson's disease (PD). This was a single-arm study with preplanned analyses conducted by dose subgroup (Low Dose or High Dose) based on the modal total daily dose (most frequent dose) over the treatment period.

Conditions

  • Parkinson's Disease (PD)

Interventions

  • ABBV-951Drug

    Solution for continuous subcutaneous infusion (CSCI)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: From first dose of study drug until 30 days following last dose of study drug (up to 480 days)
  2. Number of Participants With Adverse Events of Special InterestTime frame: From first dose of study drug until 30 days following last dose of study drug (up to 480 days)
  3. Number of Participants With Numeric Grade Equal to or Higher Than 5 and With Letter Grade Equal to or Higher Than D on the Infusion Site Evaluation ScaleTime frame: Day 1, Day 2, Week 1, Week 2, Week 3, Week 4, Week 6, Week 13, Week 26, Week 39, and Week 52
  4. Hematocrit (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  5. Hemoglobin (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  6. Red Blood Cell (RBC) Count (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  7. White Blood Cell (WBC) Count (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  8. Neutrophils (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  9. Lymphocytes (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  10. Monocytes (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  11. Absolute Platelet Count (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  12. Mean Corpuscular Hemoglobin (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  13. Mean Corpuscular Volume Concentration (MCHC) (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  14. Prothrombin Time (PT) (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  15. Activated Partial Thromboplastin Time (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  16. Blood Urea Nitrogen (BUN) (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  17. Creatinine (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  18. Creatine Phosphokinase (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  19. Total Bilirubin (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  20. Serum Alanine Aminotransferase (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  21. Serum Aspartate Aminotransferase (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  22. Serum Lactate Dehydrogenase (LDH) (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  23. Gamma-glutamyl Transferase (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  24. Alkaline Phosphatase (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  25. Sodium (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  26. Potassium (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  27. Calcium (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  28. Inorganic Phosphorus (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  29. Uric Acid (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  30. Total Cholesterol (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  31. Albumin (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  32. Glucose (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  33. Sodium Bicarbonate/CO2 (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  34. Magnesium (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  35. Creatinine Clearance (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  36. Homocysteine (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, and 52
  37. Vitamin B6 (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, and 52
  38. Vitamin B12 (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, and 52
  39. pH (Urinalysis): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  40. Specific Gravity (Urinalysis): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
  41. Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of StudyTime frame: Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)
  42. Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of StudyTime frame: Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)
  43. Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of StudyTime frame: Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)
  44. Electrocardiogram (ECG) Mean Heart Rate: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
  45. Electrocardiogram (ECG) Aggregate PR Interval: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
  46. Electrocardiogram (ECG) Aggregate QRS Duration: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
  47. Electrocardiogram (ECG) Aggregate QT Interval: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
  48. Electrocardiogram (ECG) Aggregate QTcB Interval: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
  49. Electrocardiogram (ECG) Aggregate QTcF Interval: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
  50. Electrocardiogram (ECG) Aggregate RR Interval: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52

Locations

65 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - Main /ID# 207996

    Birmingham, Alabama

  • Banner Sun Health Res Inst /ID# 208811

    Sun City, Arizona

  • The Parkinson's & Movement Disorder Institute - Fountain Valley /ID# 216126

    Fountain Valley, California

  • University of Colorado Hospital /ID# 207968

    Aurora, Colorado

  • Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 207677

    Boca Raton, Florida

  • Northwestern University Feinberg School of Medicine /ID# 208812

    Chicago, Illinois

  • Indiana Clinical Research Cent /ID# 207952

    Indianapolis, Indiana

  • Univ Kansas Med Ctr /ID# 208963

    Kansas City, Kansas

  • University of Kentucky Chandler Medical Center /ID# 207603

    Lexington, Kentucky

  • Massachusetts General Hospital /ID# 207993

    Boston, Massachusetts

  • Health Partners /ID# 207950

    Saint Paul, Minnesota

  • University of Missouri /ID# 209043

    Columbia, Missouri

  • Washington University-School of Medicine /ID# 207525

    St Louis, Missouri

  • Dartmouth-Hitchcock Medical Center /ID# 207972

    Lebanon, New Hampshire

  • Wake Radiology UNC REX Healthcare - Raleigh Office /ID# 209784

    Raleigh, North Carolina

  • Legacy Medical Group - Neurology /ID# 208031

    Portland, Oregon

  • Prisma Health Cancer Institute-Faris Road /ID# 207650

    Greenville, South Carolina

  • Neurology Consultants of Dallas - LBJ Fwy /ID# 207619

    Dallas, Texas

  • Baylor College of Medicine /ID# 207620

    Houston, Texas

  • Central Texas Neurology Consul /ID# 216918

    Round Rock, Texas

  • Univ Texas HSC San Antonio /ID# 208958

    San Antonio, Texas

  • Booth Gardner Parkinson's Care Center /ID# 208026

    Kirkland, Washington

  • Inland Northwest Research /ID# 208122

    Spokane, Washington

  • Medical College of Wisconsin /ID# 207999

    Milwaukee, Wisconsin

  • Concord Repatriation General Hospital /ID# 207628

    Concord, New South Wales, Australia

  • Westmead Hospital /ID# 207633

    Westmead, New South Wales, Australia

  • Royal Adelaide Hospital /ID# 207634

    Adelaide, South Australia, Australia

  • Alfred Health /ID# 207632

    Melbourne, Victoria, Australia

  • Perron Institute /ID# 207627

    Nedlands, Western Australia, Australia

  • AZ Sint-Jan Brugge /ID# 208178

    Bruges, Belgium

  • Groupe Sante CHC - Clinique du MontLegia /ID# 208177

    Liège, Belgium

  • Universitair Ziekenhuis Leuven /ID# 209058

    Leuven, Vlaams-Brabant, Belgium

  • University of Calgary - Movement Disorders Clinic /ID# 207342

    Calgary, Alberta, Canada

  • Centre de Recherche St-Louis /ID# 207344

    Québec, Quebec, Canada

  • Bispebjerg and Frederiksberg Hospital /ID# 207669

    Copenhagen NV, Capital Region, Denmark

  • Aarhus University Hospital /ID# 207668

    Aarhus N, Central Jutland, Denmark

  • Odense University Hospital /ID# 207871

    Odense C, Region Syddanmark, Denmark

  • Kliniken Beelitz GmbH /ID# 208600

    Beelitz-Heilstätten, Germany

  • InnKlinikum Haag /ID# 208601

    Haag, Germany

  • Universitaetsklinikum Ulm /ID# 208602

    Ulm, Baden-Wurttemberg, Germany

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.